Publications by authors named "Elizabeth I Buchbinder"

35Publications

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade.

Haematologica 2020 Sep 14;Online ahead of print. Epub 2020 Sep 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2020.258426DOI Listing
September 2020

The Evolution of Adjuvant Therapy for Melanoma.

Curr Oncol Rep 2019 11 25;21(12):106. Epub 2019 Nov 25.

Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0858-3DOI Listing
November 2019

Immunotherapy Toxicity.

Hematol Oncol Clin North Am 2019 04 28;33(2):275-290. Epub 2019 Jan 28.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Dana 2, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2018.12.008DOI Listing
April 2019

Biomarkers in Melanoma: Lessons from Translational Medicine.

Trends Cancer 2016 06 2;2(6):305-312. Epub 2016 Jun 2.

Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2016.05.003DOI Listing
June 2016

Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

J Neurooncol 2017 05;133(1):221

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2485-xDOI Listing
May 2017

The Phoenix Rises: The Rebirth of Cancer Immunotherapy.

Clin Chem 2017 07 17;63(7):1190-1195. Epub 2017 May 17.

Professor, Internal Medicine, Leader, Melanoma/Renal Cell Disease Research Team, Associate Chief, Section of Medical Oncology, Yale University, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2016.267849DOI Listing
July 2017

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.

Cancer Med 2016 11 17;5(11):3041-3050. Epub 2016 Oct 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.862DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119958PMC
November 2016

Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

J Neurooncol 2016 09 11;129(3):389-393. Epub 2016 Jul 11.

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-016-2196-8DOI Listing
September 2016

Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.

Nat Rev Clin Oncol 2016 Feb 20;13(2):77-8. Epub 2016 Jan 20.

Melanoma Disease Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215-05450, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.237DOI Listing
February 2016

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Am J Clin Oncol 2016 Feb;39(1):98-106

*Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School †Biologic Therapy Program, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000239DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892769PMC
February 2016

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.

Front Oncol 2015 22;5:202. Epub 2015 Sep 22.

Department of Medical Oncology, Melanoma Disease Center, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA , USA ; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA.

View Article

Download full-text PDF

Source
http://journal.frontiersin.org/Article/10.3389/fonc.2015.002
Publisher Site
http://dx.doi.org/10.3389/fonc.2015.00202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585112PMC
October 2015

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.

Cancer 2015 Nov 11;121(22):4007-15. Epub 2015 Aug 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29622DOI Listing
November 2015

Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.

Clin Ther 2015 Apr 6;37(4):755-63. Epub 2015 Mar 6.

Division of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2015.02.003DOI Listing
April 2015

Interferon, interleukin-2, and other cytokines.

Hematol Oncol Clin North Am 2014 Jun 3;28(3):571-83. Epub 2014 Apr 3.

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2014.02.001DOI Listing
June 2014